ResearcherNagoya University HospitalNo recent work listed
Masato Nagino
Matched on ORCID iD 0000-0002-8052-9902; OpenAlex author ID A5101806827. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 23
2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper
Papers 5
- Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Co-author DOI 10.1097/sla.0000000000005430↗
- The Anticancer Effects of Novel α-Bisabolol Derivatives Against Pancreatic Cancer. Last author DOI 10.21873/anticanres.11352↗
- α-Bisabolol Inhibits Invasiveness and Motility in Pancreatic Cancer Through KISS1R Activation. Last author PMID 26851012↗
- Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer. Last author DOI 10.1002/cam4.453↗
- Seven-signal proteomic signature for detection of operable pancreatic ductal adenocarcinoma and their discrimination from autoimmune pancreatitis. Co-author DOI 10.1155/2012/510397↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yukihiro Yokoyama · 5 shared papers, 2012–2022 · strength 0.38
- Paper Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectabl… DOI 10.1097/sla.0000000000005430↗
- Paper α-Bisabolol Inhibits Invasiveness and Motility in Pancreatic Cancer Through KISS1R Activation. PMID 26851012↗
- Paper The Anticancer Effects of Novel α-Bisabolol Derivatives Against Pancreatic Cancer. DOI 10.21873/anticanres.11352↗
- Junpei Yamaguchi · 3 shared papers, 2015–2022 · strength 0.27
- Paper Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectabl… DOI 10.1097/sla.0000000000005430↗
- Paper The Anticancer Effects of Novel α-Bisabolol Derivatives Against Pancreatic Cancer. DOI 10.21873/anticanres.11352↗
- Paper Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer. DOI 10.1002/cam4.453↗
- Toshio Kokuryo · 3 shared papers, 2015–2017 · strength 0.21
- Paper α-Bisabolol Inhibits Invasiveness and Motility in Pancreatic Cancer Through KISS1R Activation. PMID 26851012↗
- Paper The Anticancer Effects of Novel α-Bisabolol Derivatives Against Pancreatic Cancer. DOI 10.21873/anticanres.11352↗
- Paper Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer. DOI 10.1002/cam4.453↗
- Tomohiro Miwa · 2 shared papers, 2015–2017 · strength 0.14
- Takuya Ishikawa · 1 shared paper, 2022 · strength 0.14
- Suguru Yamada · 1 shared paper, 2022 · strength 0.14
- Hiroki Kawashima · 1 shared paper, 2022 · strength 0.14
- Eizaburo Ohno · 1 shared paper, 2022 · strength 0.14
- Osamu Maeda · 1 shared paper, 2022 · strength 0.14
- Yasuhiro Kodera · 1 shared paper, 2022 · strength 0.14
- Tsutomu Fujii · 1 shared paper, 2022 · strength 0.14
- Tomoki Ebata · 1 shared paper, 2022 · strength 0.14
- Takeshi Senga · 1 shared paper, 2016 · strength 0.08
- Masanori Uno · 1 shared paper, 2016 · strength 0.08
- Yoshihiko Murata · 1 shared paper, 2017 · strength 0.07
- Takeo KAWAHARA · 1 shared paper, 2012 · strength 0.03
- Kiyoshi Yanagisawa · 1 shared paper, 2012 · strength 0.03
- Hidemi Goto · 1 shared paper, 2012 · strength 0.03
- Nobumasa Mizuno · 1 shared paper, 2012 · strength 0.03
- Shigeru B. H. Ko · 1 shared paper, 2012 · strength 0.03
- Keitaro Matsuo · 1 shared paper, 2012 · strength 0.03
- Takashi Takahashi · 1 shared paper, 2012 · strength 0.03
- Kenji Yamao · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.